GlassScriptPhysician profile
Joel S Mendelson
NPI 1477612950
$2,165.41
in general payments reported to CMS, 2019-2025
20 companies · $587 in 2025
The $587 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231 · 2020: $106 · 2021: $234 · 2022: $326 · 2023: $430 · 2024: $251 · 2025: $587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,173 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,173.14 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $484.01 | 2021-2023 | Tezspire |
| Grifols USA, LLC | $273.36 | 2022-2025 | Xembify, Prolastin-C Liquid |
| Optinose US, INC. | $261.59 | 2019-2025 | |
| Ars Pharmaceuticals Operations, INC. | $192.58 | 2025 | Neffy |
| Genzyme Corporation | $151.15 | 2024-2025 | |
| Glaxosmithkline, LLC. | $146.74 | 2019-2025 | Nucala |
| Amgen INC. | $113.94 | 2022 | |
| Genentech USA, INC. | $97.09 | 2024 | Xolair |
| Sanofi-Aventis U.S. LLC | $94.99 | 2025 | |
| Csl Behring | $89.41 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $60.58 | 2019-2024 | Dupixent |
| Horizon Therapeutics Plc | $59.12 | 2020-2023 | Actimmune |
| Biocryst US Sales Co., LLC | $30.69 | 2022-2023 | Orladeyo |
| Tandem Diabetes Care, INC. | $22.87 | 2020 | |
| Greer Laboratories, INC. | $18.02 | 2025 | Oralair |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $14.85 | 2019 | |
| Janssen Biotech, INC. | $14.80 | 2022 | |
| Gilead Sciences, INC. | $13.51 | 2019 | |
| Alexion Pharmaceuticals, INC. | $13.50 | 2020 | |
| Endo Pharmaceuticals INC. | $12.61 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Mendelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.